Menu
image description

Tag: hydroxychloroquine

Actions from Pharmaceutical Companies to Preserve Hydroxychloroquine (Plaquenil) Supply

March 30, 2020 The rheumatology community has been in discussions with the U.S. Food and Drug Administration and many pharmaceutical companies about the potential shortage of hydroxychloroquine (brand name Plaquenil) in the COVID-19 epidemic, and we are seeing much progress to increase its production and availability. The LRA especially thanks Sandoz, the generics division of […] Read More

COVID-19 Frequently Asked Questions: What You Should Know

Updated April 3, 2020 The first priority of the Lupus Research Alliance is the health of our lupus community.  We have been consulting with health care authorities and monitoring the situation created by the spread of COVID-19. Please note that every lupus patient is different. If you have specific questions about your condition and/or any […] Read More

The U.S. Department of Health and Human Services Accepts Donations of Hydroxychloroquine as Possible Treatments for COVID-19 Patients

March 31, 2020 A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that millions of donated doses of hydroxychloroquine sulfate and chloroquine phosphate had been accepted into the Strategic National Stockpile. In addition, the statement announced that the Food and Drug Administration has granted Emergency Use Authorization (EUA) […] Read More

CVS Preserving Plaquenil Supply for Patients Taking It

March 26, 2020 CVS put out the following statement yesterday assuring its clients that the company is protecting a supply for people already taking hydroxychloroquine. CVS Health helping protect supply of medicines potentially useful for COVID-19 treatment CVS Caremark, the pharmacy benefit management business of CVS Health, is working with clients to implement new measures […] Read More

MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community

March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] Read More

Hydroxychloroquine: Common Lupus Drug in Testing for COVID-19

March 19, 2020 In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found to cause a severe respiratory illness in patients which was later named after the type of virus that caused it and the year it was identified (coronavirus disease 2019 or COVID-19)1 Currently there is no […] Read More

Potential New Lupus Treatment Outperforms Hydroxychloroquine in Animal Study

November 28, 2018 Anti-malaria drugs such as hydroxychloroquine are common treatments for arthritis and heat rash in patients with lupus. A new study by Target Identification in Lupus grantee Keith Elkon, MD, of the University of Washington, Seattle, and colleagues suggests that a new drug they designed works better than the commonly prescribed hydroxychloroquine in […] Read More